Ginkgo entered into a definitive agreement to acquire Zymergen in an all-stock transaction at ~$300M market capitalization. Zymergen stockholders will receive 0.9179 Ginkgo shares for each Zymergen share representing 5.25% of the pro forma combined company. The transaction is expected to close in Q1 23
The acquisition will expand the development of Ginkgo’s horizontal synthetic biology platform by integrating Zymergen’s core automation, software, data science tools, and biological assets into its Foundry for a diverse customer base & enable new growth opportunities across markets
Ginkgo will support Zymergen’s plans to evaluate strategic alternatives for their advanced materials & drug discovery businesses
Ref: PRNewswire | Image: Zymergen
